Horne, Hisani NOh, HannahSherman, Mark EPalakal, MayaHewitt, Stephen MSchmidt, Marjanka KMilne, Roger LHardisson, DavidBenitez, JavierBlomqvist, CarlBolla, Manjeet KBrenner, HermannChang-Claude, JennyCora, RenataCouch, Fergus JCuk, KatarinaDevilee, PeterEaston, Douglas FEccles, Diana MEilber, UrsulaHartikainen, Jaana MHeikkilä, PäiviHolleczek, BerndHooning, Maartje JJones, MichaelKeeman, RenskeMannermaa, ArtoMartens, John W MMuranen, Taru ANevanlinna, HeliOlson, Janet EOrr, NickPerez, Jose I APharoah, Paul D PRuddy, Kathryn JSaum, Kai-UweSchoemaker, Minouk JSeynaeve, CarolineSironen, ReijoSmit, Vincent T H B MSwerdlow, Anthony JTengström, MariaThomas, Abigail STimmermans, A MiekeTollenaar, Rob A E MTroester, Melissa Avan Asperen, Christi Jvan Deurzen, Carolien H MVan Leeuwen, Flora FVan't Veer, Laura JGarcía-Closas, MontserratFigueroa, Jonine D2019-09-182019-09-182018-04-26Sci Rep. 2018 ;8(1):6574.2045-2322http://hdl.handle.net/20.500.12105/8356E-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated E-cadherin tumor immunohistochemistry expression using tissue microarrays of 5,933 female invasive breast cancers from 12 studies from the Breast Cancer Consortium. H-scores were calculated and case-case odds ratios (OR) and 95% confidence intervals (CIs) were estimated using logistic regression. Survival analyses were performed using Cox regression models. All analyses were stratified by estrogen receptor (ER) status and histologic subtype. E-cadherin low cases (N = 1191, 20%) were more frequently of lobular histology, low grade, >2 cm, and HER2-negative. Loss of E-cadherin expression (score < 100) was associated with menopausal hormone use among ER-positive tumors (ever compared to never users, OR = 1.24, 95% CI = 0.97-1.59), which was stronger when we evaluated complete loss of E-cadherin (i.e. H-score = 0), OR = 1.57, 95% CI = 1.06-2.33. Breast cancer specific mortality was unrelated to E-cadherin expression in multivariable models. E-cadherin low expression is associated with lobular histology, tumor characteristics and menopausal hormone use, with no evidence of an association with breast cancer specific survival. These data support loss of E-cadherin expression as an important marker of tumor subtypes.engVoRhttp://creativecommons.org/licenses/by-nc-sa/4.0/Atribución-NoComercial-CompartirIgual 4.0 Internacional2970040881657410.1038/s41598-018-23733-42045-2322Scientific reportsopen access